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Abstract: The G->A transition at position 20210 in the prothrombin gene is a genetic risk factor for venous thrombosis.
Nevertheless, it is not clear if the prothrombin 20210A allele is also a genetic risk factor for arterial thrombosis.
We studied 124 patients with myocardial infarction (MI) and 182 healthy individuals to assess the possible correlation between
prothrombin gene polymorphism and MI. In addition, we analyzed 42 MI patients, who were selected as having no other secondary
risk factors and who thus have a potential genetic predisposition to infarction.
The frequencies of heterozygous carriers of the 20210A polymorphism of the gene (% GA genotype) were calculated as follows:
among the 124 patients with MI 3.23%, 42 selected patients 9.53% and among the 46 selected controls 4.35%. The prothrombin
20210A allele was detected by allele specific polymerase chain reaction.
We found no correlation between the prothrombin 20210A allele and MI. This study supports the view of that prothrombin 20210A
polymorphism is not an independent risk factor for MI.
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Introduction
Thrombotic tendency increases the risk of myocardial
infarction (MI) in some individuals, especially in young
adults. Local thrombotic occlusion in coronary arteries
plays a pathogenetic role at the site of a ruptured plaque
(1). There are several risk factors known to be causative
in the development of MI, such as hyperlipidemia,
hypertension, diabetes mellitus, obesity and cigarette
smoking. Additionally, there are some genetic markers
whose roles are still poorly understood (2).
Prothrombin (factor II) is the final effector of the
clotting cascade that leads to the formation of fibrin.
Prothrombin is the precursor of the serin protease
thrombin which plays a central role in the control of
blood coagulation by exerting both procoagulant and
anticoagulant effects (3). The prothrombin gene is
localized on chromosome 11 near the centromere, spans
approximately 21000 bp, and is composed of 14 exons
and 13 introns. The cDNA encodes a preproleader
sequence similar to that found in other vitamin K
dependent proteins (4).

Recently, a genetic polymorphism located in the 3’untranslated region of the prothrombin gene was
described. The polymorphism is due to a single base pair
substitution at position 20210 of a guanine (G) for an
adenine (A) nucleotide. As reported previously (5) the
prothrombin 20210 A allele is present in all white
subpopulations. It is thought to be more prevalent in
Mediterranean countries, especially in Israel (5.4%) and
Italy (4.5%) (5). In Turkey, the incidence (percentage) of
the 20210A allele has been reported at 2.7% (6). Blood
prothrombin levels in people with the GG genotype are
1.05 U/ml, compared with 1.32 U/ml in heterozygous
carriers of the 20210A allele. An elevated prothrombin
level in blood alone is a risk factor for venous thrombosis
(1,2,3,7,8,9,10) which indicates a likelihood that the
prothrombin 20210A allele acts through elevated plasma
prothrombin levels (5,11).
Previous research in to the correlation between
prothrombin 20210A polymorphism and MI has been
controversial. Some researchers reported 20210A
polymorphism to be a risk factor for MI (12,14,15),
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while others did not observe a positive correlation
(1,8,13). In the present study, we examined the
prevalence of the recently described 20210 G->A
substitution in the prothrombin gene in 42 men and
women with MI and 46 healthy control subjects who
were carefully chosen in order to exclude other secondary
risk factors except for smoking (19% of the MI patients
and 17% of the healthy controls were smokers).
Additionally, we analyzed 124 patients with MI having
secondary risk factors.
Materials and Methods
Study and Control Subjects
The study included 124 unselected and 42 selected
patients with MI admitted to ‹stanbul University Hospital.
It was approved by the institutional review committee
and informed consent was given by subjects. The
diagnosis of MI was based on chest symptoms, typical
electrocardiographic changes and serum enzymes. The
study also included 46 control subjects, chosen from
healthy individuals. Patients and control subjects were
selected on the basis of having had no other known
secondary risk factors for MI as determined by the
National Cholesterol Education Program (NCEP) such as
hypertension, hypercholesterolemia, diabetes mellitus or
old age.
Coronary Risk Factors
Hypertension was defined by a history of several
blood pressure measurements elevated either systolically

(> 140 mmHg) or diastolically (> 90 mmHg). Diabetes
mellitus was defined by elevated blood glucose levels after
fasting (> 7.8 mmol/l-140 mg/dl) or 2 h after 75 g of
oral glucose loading (> 11.1 mmol/l-200 mg/dl).
Hypercholesterolemia was defined by elevated total
serum cholesterol levels (> 200 mg/dl).
Laboratory Analysis
20210G->A polymorphism of the prothrombin gene
was determined from DNA extracted from peripheral
blood using the ammonium acetate method. We used
allele specific amplification to discriminate the
prothrombin allele. Two external primers (1 and 2) and 2
internal forward (nested) primers (3 and 4) were used.
Primer
1
was
a
forward
primer,
5’TCCGCCTGAAGAAGAGTGGATA3’ (nt 20064 to
20085); primer 2 was a reverse primer,
5’GAGTGCTCGGACTACCAGCGTGC3’ (nt 20333 to
20311); primer 3 was a forward primer,
5’TTCCCAATAAAAGTGACTCTCAGCA3’ (nt 20186 to
20210) and primer 4 was a forward primer
5’TTCCCAATAAAAGTGACTCTCAGCG3’ (nt 20186 to
20210). The 2 internal primers, 3 and 4, only differred
in the last nucleotide (specific to G->A substitution). The
external primers, 1 and 2, amplified the 270 bp DNA
fragment. Primers 3–2 and 4–2 amplified the148 bp
fragment. For every subject, 2 tubes were used; the first
tube with primers 1, 2 and 3 and the second tube with
primers 1, 2, 4 (Figure 1). Amplification was carried out
in 25 µl containing 100 ng of genomic DNA, 1.5 mmol/l
of MgCl2, 750 mM Tris-HCl (pH 8.8 at 25 °C), 200 mM

Figure 1. Detection of prothrombin 20210A polymorphism by allele specific polymerase chain
reaction. A1B1: Homozygote GG, A2B2: Heterozygote GA, M: Molecular Weight
Marker (Puc Mix 8).
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(NH4)2SO4, 0.1% Tween 20, 2 mM dNTPs, 400 nmol of
each primer and 1 unit of Taq polymerase. A first
denaturation step at 94 °C for 4 min was followed by 36
cycles of 94 °C for 45 s, 62 °C for 1 min and 72 °C for
1 min (16). Finaly,15 µl of each PCR product was loaded
onto 2% agarose gel.
Statistical Analysis
The frequencies of the alleles and genotypes were
compared among patients and the control groups using
Fisher’s exact test when appropriate. The genotype
frequencies in control subjects, patients and the overall
study groups – as determined using Fisher’s exact test –
were in accordance to the distribution predicted by the
Hardy-Weinberg equilibrium model. SPSS for Windows
10.0 and Microsoft Excel were used for statistical
analysis.

Results
Prothrombin 20210A polymorphism was examined in
a subgroup of Turkish patients angiographically proven to
have MI. We first examined 124 MI patients for the
presence of the GG and/or GA genotype. We determined
that the patients with MI had a frequency 96.77% GG
genotype and a 3.23% frequency GA genotype (P >
0.005; X2 = 0.808) (Table 1). As published previously,
the GA genotype frequency was determined to be 2.7%
in Turkey (6).
We further analyzed the data and selected 42 patients
having no other secondary risk factors (Table 2), but one
Table 1.

or more of whose family members had a previous history
of MI and compared these with 46 no-risk controls. Of
the selected patients 90.47% were GG and 9.53% were
GA genotypes and of the in selected controls 95.65%
were GG and 4.35% GA genotypes (Table 1) (P > 0.005;
X2 = 0,926).
In conclusion, we did not observe any statistically
significant increase in the frequency of the prothrombin
20210 GA genotype in either the unselected and selected
patient groups with MI, compared with healthy
individuals.
Discussion
Prothrombin gene polymorphism is characterized by
the single base pair substitution of guanine for an adenine
nucleotide at position 20210. The prothrombin level of A
allele carriers is higher than that of non-carriers (14). The
higher level of prothrombin causes more growth of fibrin
clots and may plug the blood vessels. Therefore, this
mutated allele had been described as a moderate risk
factor for venous thrombosis with a frequency level of
0.7-4% in healthy individuals from different countries
(13). When the gene was investigated for arterial
thrombosis, controversial results emerged: some groups
reported a positive correlation between this mutation and
MI (12,14,15), whereas others did not (1,8,13).
Our main goal in this study was to clarify the question
of whether there is a correlation between prothrombin
gene polymorphism (nt20210A) and the MI in a
subgroup of the Turkish populations.

Statistically, there is no difference in the distribution of the prothrombin GG and GA genotypes between patients with MI and the healthy
controls.
Prevalence of the prothrombin gene 20210 G A variant among MI patients and controls.
Genotype
GG

GA

Unselected MI patients

n = 124
%

120
96.77

4
3.23

Turkish Population*

n = 182
%

177
96.3

5
2.7

Selected patients group

n = 42
%

38
90.47

4
9.53

Control group

n = 46
%

44
95.65

2
4.35

p

x2

0.531

0.808

0.336

0.926

* Reference 6
P > 0.05
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Table 2.

Selected patients and healthy controls were matched with cholesterol, diabetes, ldl, hdl, triglyceride, bmi and gender. Family history and
age were not matched.
Major cardiovascular risk factors in selected patients and controls.

Risk Factors

Patients (n: 42)

Controls (n: 46)

P

Cholesterol (mg/dl)
HDL (mg/dl)
LDL (mg/dl)
Glucose (mg/dl)
Triglyceride (mg/dl)
BMI
Age
Female/Male
MI history
Positive % (n)
Negative % (n)

168.69 ± 24.05
43.40 ± 9.69
103.31 ± 19.45
93.31 ± 6.56
122 ± 40.72
24.5 ± 2.23
38.58 ± 11.3
36.78 ± 13.17

165.74 ± 24.12
47.22 ± 10.44
87.57 ± 24.06
86.96 ± 10.21
119.54 ± 45.52
24.4 ± 2.28
49.82 ± 17.04
61.28 ± 12.37

0.25
0.675
0.217
0.033
0.526
0.165

66.7 (28)
3.33 (14)

6.52 (3)
93.48 (43)

P < 0.05

40.48 (17)
59.52 (25)

41.31 (19)
58.69 (27)

0.937

Gender
Female % (n)
Male % (n)

Although our findings are consistent with some of the
previously published results, they differ significantly from
a few others. For example Doggen et al. found that
prothrombin 20210A allele carriership was associated
with a 50% increase in risk of MI in 560 men aged < 70
years (14). Another group reported that the prothrombin
20210A allele increased the risk of MI in young women,
especially in those with other major risk factors for
coronary heart disease (15). In our study, there were
124 unselected patients with MI and 42 selected MI
patients 46 control cases and most of them were male.
This could be one of the reasons for the discrepancy
among the several groups.

0.082

fold (18). We are currently in the process of exploring of
a possible additive correlation of several molecular
markers as being genetic inducers for MI.
In conclusion, it appears that there was no correlation
between prothrombin 20210A mutation and MI in the
patient group we examined. After this initial study, we
plan to continue analyzing the synergistic effects of the
suggested genetic risk factors by increasing the number
of patients examined.
Corresponding author:
Nihan ERG‹NEL ÜNALTUNA
Zeytino¤lu cad., Yaren sok., Ayd›n Apt.

Interestingly, there have been some reports that
showed a synergistic effect of several thrombogenetic
risk factors such as FV G1691A, prothrombin G20210A
and MTHFR 677C->T which increase the risk of MI 9-
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